In relation to neurological disorders, PP2A has been suggested as a possible treatment target for neurological disorders Alzheimer’s disease (53) and has been recently implicated in Tau pathology of Parkinson’s disease (54). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.